Achieve Life Sciences, Inc. (ACHV) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Achieve Life Sciences (ACHV) Q1 2026: $180M Financing Secured, U.S. Manufacturing Shift De-Risks Commercial Launch
  May 12, 2026
• Achieve Life Sciences (ACHV) Q4 2025: U.S. Manufacturing Shift Secures Launch Path for First New Smoking Cessation Drug in 20 Years
  March 24, 2026
• Achieve Life Sciences (ACHV) Q3 2025: FDA Priority Voucher Cuts Vaping Launch Timeline by 8 Months
  November 06, 2025
• Achieve Life Sciences (ACHV) Q2 2025: $49M Capital Raise Primes Cytisinicline Launch Path
  August 07, 2025
• Achieve Life Sciences (ACHV) Q3 2024: $20M SVB Loan Refinancing Extends Runway for NDA Push
  November 07, 2024
• Achieve Life Sciences (ACHV) Q2 2024: FDA Breakthrough Status Accelerates Vaping Indication Path
  August 13, 2024
• Achieve Life Sciences (ACHV) Q1 2024: $124M Financing Secured as NDA Pathway Clears for Cytosinicline
  May 09, 2024
• Achieve Life Sciences (ACHV) Q4 2023: $124M Financing Secured to Accelerate Cytisinicline NDA Path
  March 28, 2024
• Achieve Life Sciences (ACHV) Q3 2023: Operating Loss Cut 46% as Cytisinicline Nears NDA Milestone
  November 09, 2023

Browse all companies